US FDA Grants Orphan Exclusivity for ALS Drug Radicava ORS

Mitsubishi Tanabe Pharma said that the US FDA has awarded seven years of orphan drug exclusivity for its oral suspension version of the ALS therapy Radicava (edaravone), Radicava ORS. The designation was granted on March 28. Radicava ORS is a...read more